ALCAM and nonpapillary renal cell carcinoma: However, to provide a solid theoretical basis for the development of new drugs for ccRCC treatment, further research is needed to clarify the specific mechanisms by which FDX1 regulates FMR1 and the effects of FMR1 on its downstream pathways, including ALCAM.